GlassScriptPhysician profile
Curtis P Page
NPI 1295730539
$15,917.24
in general payments reported to CMS, 2019-2025
69 companies · $8,076 in 2025
The $8,076 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $334 · 2021: $1,145 · 2022: $1,480 · 2023: $1,548 · 2024: $2,012 · 2025: $8,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,736 · Consulting Fee: $5,250 · Travel and Lodging: $632 · Entertainment: $17.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,736.26 |
| Consulting Fee | $5,250.00 |
| Travel and Lodging | $631.72 |
| Entertainment | $17.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $6,655.04 | 2019-2025 | Kisunla, Mounjaro, Jardiance |
| Abbvie INC. | $1,424.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $873.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $834.01 | 2019-2025 | Jardiance |
| Pfizer INC. | $670.97 | 2019-2025 | |
| Novo Nordisk INC | $592.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $552.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $440.30 | 2019-2024 | |
| Mylan Specialty L.P. | $364.46 | 2019-2024 | Yupelri |
| Amgen INC. | $259.98 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Eisai INC. | $257.93 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.10 | 2022-2025 | |
| Abbott Laboratories | $169.00 | 2021-2025 | Freestyle Libre 3, Confirm Rx, Prodigy |
| Sanofi-Aventis U.S. LLC | $163.95 | 2019-2023 | |
| Dexcom, INC. | $123.46 | 2022-2025 | Dexcom G6 Transmitter |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.